Karen Freshwater, PA
Medical · Kalamazoo, MINPI 1467685982
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Sanofi at 55.4% of the total. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $54.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$10K
- Bristol Myers Squibb$1K
- Teva Pharmaceuticals USA, Inc.$904
- Cycle Pharmaceuticals Inc$855
- TG Therapeutics, Inc.$749
- EMD Serono, Inc.$715
- plus $4K from 31 others
What the payments were for
- Consulting fees$7,34139%
- Speaking & faculty fees$8555%
- Travel & lodging$1,0746%
- Food & beverage$9,10849%
- Education$2081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 37 | $10,304 |
| Bristol Myers Squibb | 77 | $1,189 |
| Teva Pharmaceuticals USA, Inc. | 54 | $904 |
| Cycle Pharmaceuticals Inc | 2 | $855 |
| TG Therapeutics, Inc. | 22 | $749 |
| EMD Serono, Inc. | 16 | $715 |
| Biogen | 22 | $617 |
| Novartis | 20 | $511 |
| Genentech USA, Inc. | 6 | $437 |
| AbbVie | 14 | $309 |
| Johnson & Johnson(2 entities) | 6 | $272 |
| E.r. Squibb & Sons, L.L.C. | 4 | $252 |
| Boston Scientific | 1 | $209 |
| MDD US Operations, LLC | 3 | $138 |
| Eisai Inc. | 6 | $127 |
| Acadia Pharmaceuticals Inc | 7 | $121 |
| Supernus Pharmaceuticals, Inc. | 4 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $83 |
| Banner Life Sciences, LLC | 4 | $83 |
| Sunovion Pharmaceuticals Inc. | 3 | $77 |
| Kyowa Kirin, Inc. | 3 | $54 |
| UCB, Inc. | 2 | $51 |
| Neurocrine Biosciences, Inc. | 3 | $50 |
| Pfizer | 3 | $49 |
| Abbott | 2 | $42 |
| Amgen(2 entities) | 2 | $41 |
| SK Life Science, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $26 |
| AstraZeneca | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Adamas Pharmaceuticals, Inc. | 2 | $23 |
| Neurelis, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,586 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 57 | $315,353 |
| AubagioTeriflunomide | 20 | $181,370 |
| Kesimpta PenOfatumumab | 12 | $123,432 |
| ZeposiaOzanimod Hydrochloride | 13 | $114,690 |
| BetaseronInterferon Beta-1b | 13 | $110,876 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $105,471 |
| VumerityDiroximel Fumarate | 11 | $87,641 |
| GocovriAmantadine Hcl | 27 | $87,383 |
| Glatiramer Acetate | 38 | $64,969 |
| Dimethyl Fumarate | 24 | $63,591 |
| Teriflunomide | 90 | $55,243 |
| RytaryCarbidopa/Levodopa | 42 | $53,182 |
| Emgality PenGalcanezumab-Gnlm | 47 | $30,916 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 593 | $29,601 |
| Dalfampridine ErDalfampridine | 67 | $22,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $121 | $315,35357 claims |
| SanofiAubagio | $10,304 | $181,37020 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $252 | $114,69013 claims |
| BiogenVumerity | $617 | $87,64111 claims |
| MDD US Operations, LLCGocovri | $138 | $87,38327 claims |
| Amneal Pharmaceuticals LLCRytary | $14 | $53,18242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Kalamazoo
- Steven StoneKalamazoo$200K
- Caleb YoungbloodBerkley$215K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.